May 7, 2025 07:00 AM EDTUpdated 11:21 AM

CRISPR Therapeutics' gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

Ryan Cross

Senior Science Correspondent

CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower the risk of heart disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CRISPR Therapeutics' gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

What Vinay Prasad means for CBER, vaccines, drug approvals and more

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

FDA's ODAC will review drugs for four different cancers at meeting in May

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

Senior Science Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

CRISPR Therapeutics' gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%